Alterola Biotech, Inc.

As of September 30, 2024, Alterola Biotech, Inc. carries a market capitalization of 5.87M, placing it among publicly traded companies globally. Its enterprise value stands at 7.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2024, Alterola Biotech, Inc. has 1.47B shares outstanding.

These figures are as of September 30, 2024.

As of September 30, 2024, Alterola Biotech, Inc. maintains a current ratio of 0.32, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -104.30, indicating conservative leverage, while an interest coverage ratio of -7.56 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -298.41, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Alterola Biotech, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended September 30, 2024, Alterola Biotech, Inc. generated - - in revenue and converted that into -2.78M in net income, yielding earnings per share of 0.00. EBITDA reached -2.55M, while operating income came in at -2.55M.

As of September 30, 2024, Alterola Biotech, Inc. holds 82,720.00 in cash and equivalents against 2.35M in total debt, resulting in a net debt position of 2.27M. Total book value stands at -2.05M, with working capital of -2.47M providing operational flexibility.

Alterola Biotech, Inc. produced -2.32M in operating cash flow over the twelve months ended September 30, 2024. After subtracting - - in capital expenditures, free cash flow totaled -2.32M - equivalent to 0.00 per share.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -41.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -46.27, meaning Alterola Biotech, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Alterola Biotech, Inc.'s most recent stock split took place on August 26, 2010 with a 1:10 split ratio.

As of September 30, 2024, Alterola Biotech, Inc. has an Altman Z-Score of -22.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.